UNIGE document Scientific Article - Review
previous document  unige:20569  next document
add to browser collection

Integrating novel agents into multiple myeloma treatment - current status in Switzerland and treatment recommendations

Taverna, C.
Bargetzi, M.
Betticher, D.
Gmur, J.
Gregor, M.
Heim, D.
Hess, U.
Ketterer, N.
show hidden authors show all authors [1 - 13]
Published in Schweizerische medizinische Wochenschrift. 2010, vol. 140, p. w13054
Abstract The treatment of multiple myeloma has undergone significant changes in the recent past. The arrival of novel agents, especially thalidomide, bortezomib and lenalidomide, has expanded treatment options and patient outcomes are improving significantly. This article summarises the discussions of an expert meeting which was held to debate current treatment practices for multiple myeloma in Switzerland concerning the role of the novel agents and to provide recommendations for their use in different treatment stages based on currently available clinical data. Novel agent combinations for the treatment of newly diagnosed, as well as relapsed multiple myeloma are examined. In addition, the role of novel agents in patients with cytogenetic abnormalities and renal impairment, as well as the management of the most frequent side effects of the novel agents are discussed. The aim of this article is to assist in treatment decisions in daily clinical practice to achieve the best possible outcome for patients with multiple myeloma.
Keywords AgedAntineoplastic Agents/adverse effects/*therapeutic useBiopsy, NeedleBone Marrow/drug effects/pathologyBone Marrow TransplantationBoronic Acids/adverse effects/therapeutic useCombined Modality TherapyDose-Response Relationship, DrugDrug Administration ScheduleDrug Resistance, Neoplasm*Evidence-Based MedicineHumansMiddle AgedMultiple Myeloma/diagnosis/*drug therapy/pathologyNeoplasm Recurrence, Local/drug therapy/pathologyPlasma Cells/drug effects/pathologyPyrazines/adverse effects/therapeutic useRetreatmentSwitzerlandThalidomide/adverse effects/analogs & derivatives/therapeutic use
PMID: 20458652
Full text
This document has no fulltext available yet, but you can contact its author by using the form below.
Research group Analyses cellulaires et moléculaires des hémopathies malignes (929)
(ISO format)
TAVERNA, C. et al. Integrating novel agents into multiple myeloma treatment - current status in Switzerland and treatment recommendations. In: Schweizerische medizinische Wochenschrift, 2010, vol. 140, p. w13054. https://archive-ouverte.unige.ch/unige:20569

116 hits

0 download


Deposited on : 2012-05-22

Export document
Format :
Citation style :